Welcome to our dedicated page for Arbutus Biopharm SEC filings (Ticker: ABUS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Analyzing Arbutus Biopharma's SEC filings reveals the financial realities of clinical-stage drug development and the progress of hepatitis B cure programs. The company's regulatory documents contain details that press releases often summarize but rarely explore in depth.
10-K annual reports disclose Arbutus's cash runway calculations, a critical metric for biotechs without product revenue. These filings detail research and development expenses across individual programs, showing which drug candidates receive the most investment. The reports also explain the company's intellectual property position, including its lipid nanoparticle (LNP) technology patents and any licensing arrangements generating royalty income.
10-Q quarterly reports provide updated cash positions and burn rates, helping investors assess how long operations can continue before additional financing becomes necessary. Clinical trial expenses fluctuate based on enrollment and study phases, with these variations reflected in the financials. Stock-based compensation details show how equity is used to attract and retain scientific talent.
8-K filings capture material events including partnership agreements, licensing deals, and significant clinical milestones. For Arbutus, these often relate to HBV program updates or changes to the company's strategic direction. Our AI summaries highlight the key disclosures within each 8-K, saving time spent reading boilerplate language.
Form 4 insider transactions track when executives and directors buy or sell ABUS shares. In the biotech sector, insider activity can signal confidence levels during critical development periods. Access all Arbutus SEC filings with AI-powered explanations that translate regulatory language into actionable insights.
Arbutus Biopharma Corporation filed a current report stating that its Chairperson, Chief Executive Officer and President, Lindsay Androski, is giving a presentation on the company’s ongoing patent litigation involving its lipid nanoparticle technology used in COVID-19 vaccines at Roivant Sciences Ltd.’s 2025 Investor Day. The related litigation slide deck is furnished as Exhibit 99.1 and incorporated by reference.
The company notes that these slides contain forward-looking statements about its plans and expected timing for the litigation. It cautions that these statements rely on assumptions and are subject to significant uncertainties, including risks associated with litigation generally, economic and market conditions, possible shifts in strategic focus, and the sufficiency of its cash resources. Arbutus refers readers to risk discussions in its annual and quarterly SEC reports and other continuous disclosure filings.
Arbutus Biopharma (ABUS) reported that it furnished a press release announcing its financial results for the third quarter ended September 30, 2025. The company also made available an updated corporate presentation.
The press release is provided as Exhibit 99.1 under Item 2.02, and the corporate presentation is filed as Exhibit 99.2 under Item 8.01. Both were dated November 13, 2025 and are incorporated by reference.
Arbutus Biopharma (ABUS) filed its Q3 2025 report. Total revenue was $529,000, driven by $280,000 from collaborations and $249,000 of non-cash royalty revenue. Operating expenses were $9.2 million, reflecting lower R&D and G&A after earlier cost actions, and the company reported a net loss of $7.7 million, or $0.04 per share.
Year-to-date, revenue reached $13.0 million, primarily from recognizing $10.4 million of previously deferred revenue after terminating the Qilu license; net loss narrowed to $29.7 million. Cash, cash equivalents and marketable securities totaled $93.7 million as of September 30, 2025, with no debt, and management believes resources fund operations for at least the next 12 months. The company recorded $12.6 million of restructuring costs year-to-date tied to a 57% workforce reduction, exiting its headquarters, and discontinuing in-house research. As of November 11, 2025, 192,324,017 common shares were outstanding. Arbutus continues patent actions related to its LNP technology, with a U.S. trial against Moderna set for March 2026 and a September 2025 claim construction ruling in the Pfizer/BioNTech case that it considers favorable.
Two Seas Capital and affiliated reporting persons disclosed beneficial ownership of 10,443,317 common shares of Arbutus Biopharma (symbol: ABUS), representing 5.4% of the outstanding class as of June 30, 2025. The stake is held in two funds — 7,472,841 shares in the Two Seas Global (Master) Fund and 2,970,476 shares in the Two Seas LNP Opportunities (Master) Fund — and the reporting persons state they have sole voting and sole dispositive power over all reported shares. The filing includes a certification that the securities are held in the ordinary course of business and were not acquired with the purpose of changing or influencing control of the issuer. The disclosure references a total share count of 191,641,511 common shares used to calculate the percentage.
ABUS Q2-25 showed a sharp swing to profitability as one-time license revenue and deep cost cuts outweighed lower investment income. Total revenue rose to $10.7 m from $1.7 m a year earlier, driven mainly by recognition of $9.6 m in deferred revenue after the June termination of the Qilu partnership, which also returns worldwide rights to imdusiran. Non-cash royalty revenue from Alnylam’s ONPATTRO contributed $0.5 m.
Operating expenses fell 60% YoY to $9.3 m following a 57% workforce reduction, facility exit and R&D scale-back; Q1 restructuring charges totaled $12.4 m. As a result, operating income reached $1.5 m versus a $21.6 m loss last year, and net income reached $2.5 m ($0.01/share) versus a $19.8 m loss. For the six months, the company still posted a $22.0 m loss, but cash burn declined (operating cash outflow $29.1 m vs $33.8 m).
Cash, cash equivalents and short-term securities were $98.1 m at 30-Jun-25 (down from $122.6 m at year-end) with no debt; management expects runway of ≥12 months. Total assets fell to $103.3 m, liabilities to $20.3 m and equity to $83.0 m. Contingent consideration stands at $10.8 m and the liability from royalty-sale to OMERS declined to $3.9 m.
Key catalysts include Phase 2 data from imdusiran combinations, ongoing Phase 1a/1b dosing of oral PD-L1 inhibitor AB-101, and patent litigation milestones against Moderna and Pfizer/BioNTech (trial in Mar-26). Cost-control measures and regained global rights position Arbutus for partnering, but termination of Qilu removes future milestone streams.
FAQ
What is the current stock price of Arbutus Biopharm (ABUS)?
What is the market cap of Arbutus Biopharm (ABUS)?
